GlassScriptPhysician profile
Kristin J Witfill
NPI 1396764460
$383,840.17
in general payments reported to CMS, 2019-2025
38 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,173 · 2021: $50K · 2022: $125K · 2023: $58K · 2024: $76K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $170K · Food and Beverage: $6,878 · Travel and Lodging: $5,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,560.00 |
| Food and Beverage | $6,877.65 |
| Travel and Lodging | $5,747.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $374,969.92 | 2019-2025 | Nemluvio |
| Organogenesis INC. | $2,420.78 | 2021-2024 | Novachor, Nushield, Affinity |
| Abbvie INC. | $1,224.32 | 2019-2025 | Botox, Skyrizi |
| Kerecis Limited | $610.99 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Biofrontera INC. | $596.79 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Epsfl, LLC | $556.60 | 2023 | |
| Sun Pharmaceutical Industries INC. | $467.14 | 2022-2025 | Odomzo, Blu-U |
| Lilly USA, LLC | $354.87 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Incyte Corporation | $310.87 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $295.44 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $196.27 | 2024-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $178.17 | 2019-2025 | |
| Pfizer INC. | $159.33 | 2019-2022 | |
| Allergan, INC. | $154.57 | 2019 | |
| Genzyme Corporation | $146.43 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Witfill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.